Delivery Order #75N91026F00023

Leidos Biomedical Research Awarded Delivery Order for Drug Formulation Studies

This delivery order contract has been awarded to Leidos Biomedical Research, Inc., a subsidiary of Leidos Holdings, Inc., specializing in biomedical research and development. The contract focuses on specialized drug product formulation, manufacturing, and stability studies specifically for bethanechol chloride intended for Phase I clinical trials. This work is significant as it supports early-stage clinical research vital for the development of new therapeutic options, potentially benefiting public health outcomes. The scope includes comprehensive formulation and stability testing necessary to ensure the safety and efficacy of the drug candidate in clinical use. This delivery order builds upon a larger, multi-billion dollar Federally Funded Research and Development Center contract awarded competitively to Leidos Biomedical Research to support the National Cancer Institute, indicating strong prior performance and expertise. The contract was awarded on a competitive basis and will be performed over a multi-year period at the Frederick, Maryland location, encompassing the duration necessary to complete these critical pharmaceutical studies.

Description

FFRDC DRUG PRODUCT FORMULATION, MANUFACTURE, AND STABILITY STUDIES OF BETHANECHOL CHLORIDE FOR PHASE I CLINICAL TRIALS

View original record